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Mounting evidence indicates that in chronic inflammatory arthritis (CIA), QTc prolongation 
is frequent and correlates with systemic inflammatory activation. Notably, basic studies 
demonstrated that inflammatory cytokines induce profound changes in potassium 
and calcium channels resulting in a prolonging effect on cardiomyocyte action poten-
tial duration, thus on the QT interval on the electrocardiogram. Moreover, it has been 
demonstrated that in rheumatoid arthritis (RA) patients, the risk of sudden cardiac death 
is significantly increased when compared to non-RA subjects. Conversely, to date no 
data are available about torsades de pointes (TdP) prevalence in CIA, and the few cases 
reported considered CIA only an incidental concomitant disease, not contributing factor 
to TdP development. We report three patients with active CIA developing marked QTc 
prolongation, in two cases complicated with TdP degenerating to cardiac arrest. In these 
patients, a blood sample was obtained within 24 h from TdP/marked QTc prolongation 
occurrence, and levels of IL-6, TNFα, and IL-1 were evaluated. In all three cases, IL-6 was 
markedly elevated, ~10 to 100 times more than reference values. Moreover, one patient 
also showed high circulating levels of TNFα and IL-1. In conclusion, active CIA may 
represent a currently overlooked QT-prolonging risk factor, potentially contributing in the 
presence of other “classical” risk factors to TdP occurrence. In particular, a relevant role 
may be played by elevated circulating IL-6 levels via direct electrophysiological effects 
on the heart. This fact should be carefully kept in mind, particularly when recognizable 
risk factors are already present and/or the addition of QT-prolonging drugs is required.
Keywords: torsades de pointes, chronic inflammatory arthritis, systemic inflammation, interleukin-6, rheumatoid 
arthritis, psoriatic arthritis, sudden death
INtRoDUCtIoN
Torsades de pointes (TdP) is a polymorphic ventricular tachycardia exclusively occurring in 
patients with long QT syndrome (LQTS). TdP usually develops in patients presenting a marked 
QTc prolongation (>500 ms) and is life-threatening, as it can degenerate into ventricular fibrillation 
(VF) and sudden cardiac death (SCD). In most TdP cases, multiple QTc-prolonging factors need 
taBLe 2 | Disease-associated and inflammatory parameters of patients by case.
patient Disease ongoing treatment (dosage) Rheumatoid 
factor
esR  
(mm/h)
Fibrinogen  
(mg/dL)a
CRp  
(mg/dL)
plasma cytokine levels (pg/mL)
IL-6 tNFα IL-1
1 Rheumatoid arthritis Methotrexate (20 mg/
week) + leflunomide (20 mg/day)
Positive 62 508 5.55 26.24 81.35 5.95
2 Rheumatoid arthritis Prednisone (6.25 mg/day) Positive 82 722 1.21 9.19 0.37 0.11
3 Psoriatic arthritis Methylprednisolone (4 mg/day) Negative NA 600 5.53 49.54 1.64 0.24
ESR, erythrocyte sedimentation rate (reference values: <25 mm/h); CRP, C-reactive protein (reference values: <0.5 mg/dL); IL-6, interleukin-6 (reference values: 0.49–1.25 pg/mL)b; 
TNFα, tumor necrosis factor alpha (reference values: 0.6–3.24 pg/mL)b; IL-1, interleukin-1 (reference values: 0.08–0.29 pg/mL)b; NA, not available.
Bold indicate parameters above reference values.
aFibrinogen reference values: 170–410 mg/dL.
bCytokine level range measured in an internal reference group of healthy controls.
taBLe 1 | Demographic, electrocardiographic, and clinical characteristics of patients by case.
patient age Gender Qtc (ms) tdp Cardiac 
arrest
Concomitant Qtc-prolonging factors
Non-pharmacologic Drugs
1 53 ♂ 520 Yes Yes Acute coronary syndrome, heart failure, diabetes mellitus (type II), hypocalcemia, 
anti-Ro/SSA
–
2 87 ♀ 550 Yes Yes Heart failure, complete AVB, hypothyroidism, chronic kidney disease –
3 82 ♀ 870 ND No Acute coronary syndrome, left ventricular hypertrophy, diabetes mellitus (type II), 
chronic kidney disease, hypokalemia, hypocalcemia, hypomagnesemia
Escitalopram, quetiapine, 
rivastigmine, trazodone
TdP, torsades de pointes; AVB, atrioventricular block; anti-Ro/SSA, anti-Ro/SSA antibodies; ND, not documented.
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to be simultaneously present, most often QT-prolonging drugs 
and electrolyte imbalances (1). Other currently known causes 
of acquired LQTS and TdP include structural heart diseases, 
bradyarrhythmias, endocrine disorders, autoimmunity (anti-Ro/
SSA antibodies), liver diseases, nervous system injuries, HIV 
infection, starvation, hypothermia, and toxins (1–3).
Mounting recent evidence indicates that in chronic inflam-
matory arthritis (CIA), particularly rheumatoid arthritis (RA), 
QTc prolongation is relatively frequent and correlates with the 
degree of systemic inflammatory activation (4–10). Intriguingly, 
many basic studies point to direct electrophysiological effects of 
inflammatory cytokines on the cardiomyocyte action potential 
duration (APD) (4, 11–19). Moreover, it has been demonstrated 
that in RA patients, the risk of SCD is significantly increased 
when compared to non-RA subjects (4, 20). Conversely, to date 
no data are available about the prevalence of TdP in CIA, and 
only few cases reporting TdP occurrence in RA patients were 
described (21–28). Notably, in all cases, RA was considered only 
an incidental concomitant disease, not a contributing factor to 
TdP development.
We report three CIA patients with active disease and elevated 
circulating IL-6 levels, developing marked QTc prolongation, 
in two cases complicated with TdP degenerating to cardiac 
arrest.
BaCKGRoUND
Local Ethical Committee approved the study, and patients gave 
their oral and written informed consent in accordance with the 
Principles of the Declaration of Helsinki.
patient 1
A 53-year-old man with no previous cardiac history was admitted 
for exertional chest pain and dyspnea for few days. His medical 
history was significant for a poorly controlled type II diabetes 
mellitus and long-standing RA. Few weeks before, the patients 
was hospitalized in a Rheumatologic Unit for disease reactiva-
tion, and immunosuppressive therapy was started (high-dose 
subcutaneous methotrexate plus leflunomide) (Tables 1 and 2). 
Current medications also included metformin and glibencla-
mide. The body mass index (BMI) was 31.1 (class I obesity). 
The ECG on admission showed T-wave inversion in peripheral 
and precordial left leads and QTc prolongation (520 ms), as well 
as frequent polymorphic ventricular ectopic beats (Figure 1A). 
Laboratory investigation revealed elevation in cardiac enzymes 
(troponin I 5.07 ng/mL, r.v. <0.07) and brain natriuretic peptide 
(1,091  ng/L; r.v. <100), increased A1c (glycated hemoglobin) 
(9.3%, r.v. 4.3–5.9), and moderate hypocalcemia (7.9  mg/
dL, r.v. 8.8–10.5). Potassium and magnesium were normal. 
Inflammatory markers were elevated [C-reactive protein (CRP) 
5.55  mg/dL, r.v. <0.5; erythrocyte sedimentation rate (ESR) 
67  mm/h, r.v. <25; fibrinogen 508  mg/dL, r.n. 170–410], and 
both rheumatoid factor and anti-Ro/SSA antibodies tests were 
positive (Tables  1 and  2). A complete blood count showed 
neutrophilia (white blood cell count: 9,500  ×  103/μL, neu-
trophils 78%), with normal values of hemoglobin (12.0  g/dL; 
mean corpuscular volume 91 fL) and platelets (277 × 103/μL). 
Echocardiography documented severe left ventricular dysfunc-
tion [ejection fraction (EF) ~20%], and coronary angiography 
demonstrated critical three vessel disease. The patient was 
treated with diuretics and vasodilators, and then underwent 
FIGURe 1 | eCG monitoring findings in patient 1. (a) On admission: frequent polymorphic ventricular ectopic beats with couplets and triplets and QTc 
prolongation (520 ms). (B,C) Recurrent episodes of torsades de pointes, with degeneration to ventricular fibrillation (C). Red vertical lines show QT interval.
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triple coronary artery bypass grafting surgery. Although the 
immediate postoperative period was uneventful, 3 days later, he 
suddenly presented with two episodes of TdP, the second one 
rapidly degenerating to VF (Figures  1B,C) that was reversed 
by DC-shock. Intravenous magnesium sulfate and calcium 
gluconate were started, and coronary angiography was repeated. 
Since normal function of coronary grafts was demonstrated, a 
residual critical stenosis of the right coronary artery was treated 
by angioplasty and stenting. Nevertheless, a few hours later, 
further episodes of TdP with VF degeneration occurred, and 
the patient underwent temporary ventricular pacing. In the next 
days, although ventricular arrhythmias did not recur, a per-
manent implantable cardioverter defibrillator was implanted. 
Notably, the recently introduced immunosuppressive treatment 
was maintained during hospitalization, and the patient showed 
a progressive normalization of the inflammatory activation, 
as demonstrated by the serial assessment of fibrinogen levels 
(500, 448, and then 415  mg/dL before discharge). Long-term 
follow-up demonstrated the improvement of left ventricular 
function with recurrence of neither life-threatening arrhyth-
mias nor ischemic events. Moreover, RA treatment maintained 
the disease in remission, and QTc stably remained near-normal/
slightly prolonged (450–460 ms) (Figure S1 in Supplementary 
Material).
patient 2
An 87-year-old woman developed an out-of-hospital cardiac 
arrest during the nighttime and was successfully treated by 
defibrillation. The medical history included hypertension, 
heart failure, complete atrioventricular block, paroxysmal 
atrial fibrillation, previous single-chamber pacemaker (PM) 
VVI implantation (Vitatron C10 S), cerebrovascular disease, 
chronic kidney disease, and hypothyroidism. Moreover, she 
had a history of RA that was poorly controlled by steroid 
treatment. Current medications were warfarin, furosemide, 
amlodipine, atenolol, l-thyroxine, and prednisone. The ECG 
on admission demonstrated atrioventricular dissociation with 
low-rate PM-induced ventricular beats (45  bpm), alternating 
with narrow beats from a junctional escape revealing significant 
QTc prolongation (550  ms, Figures  2A,B). Bradycardia was 
due to activation of “sleep-function,” an algorithm aimed to 
reduce ventricular pacing by lowering nocturnal pacing rate. 
Laboratory values were remarkable for inflammatory activa-
tion (CRP 1.21  mg/dL, ESR, 82  mm/h, fibrinogen 722  mg/
dL) (Table  2) and positive rheumatoid factor, while anti-Ro/
SSA antibodies were negative and electrolytes were normal. 
A complete blood count showed increased white blood cell count 
(15,900  ×  103/μL) with neutrophilia (neutrophils 88%), low 
hemoglobin values (11.6 g/dL; mean corpuscular volume 91 fL), 
and normal platelet count (268 ×  103/μL). Echocardiography 
revealed left ventricular hypertrophy (LVH) and moderate 
systolic dysfunction (EF~40%) with PM-induced ventricular 
septum dyssynchrony. Shortly after admission, ECG monitor-
ing showed repeated episodes of TdP (Figure 2C) treated with 
DC-shock. Intravenous magnesium sulfate was started, and PM 
was reprogramed with a stimulation rate of 110 bpm. As a result, 
electric storm ceased, and the patient’s clinical condition rapidly 
improved. In the next days, no further arrhythmic events were 
recorded. Upgrading to dual-chamber PM was performed, and 
the patient was discharged with the recommendation to follow-
up with a rheumatologist to optimize the immunosuppressive 
therapy for the underlying RA.
patient 3
An 82-year-old woman was admitted for palpitations and 
dizziness. Moreover, it was reported that out-of-hospital 
ECG monitoring showed runs of ventricular tachycardia 
(no documentation available). Her medical history included 
hypertension, Alzheimer’s disease, diabetes mellitus (type II), 
chronic kidney disease, glaucoma, and breast cancer. She also 
had a history of psoriatic arthritis (PsA) for several years that 
was effectively controlled with corticosteroids, methotrex-
ate, and TNF-inhibitors. However, for several months, she 
was undertreated for renal, ocular, and oncologic conditions. 
Current medications included ramipril, hydrochlorothiazide, 
metformin, letrozole, lansoprazole, methylprednisolone, and, 
among potentially QT-prolonging drugs, quetiapine, escit-
alopram, rivastigmnine, and trazodone (Table 1). The BMI was 
29.6 (overweight). On admission, ECG demonstrated sinus 
rhythm with sporadic ventricular ectopic beats, diffuse T-wave 
inversion with T-wave alternans, and marked QTc prolonga-
tion (690–870  ms; Figure  3). Blood tests were significant for 
elevated troponin T levels (227 ng/mL; r.v. <15) and electrolytes 
imbalance (low levels of potassium, calcium, and magnesium), 
and high levels of inflammatory markers (CRP 5.53  mg/dL, 
fibrinogen 600  mg/dL) (Table  2). A1c (glycated hemoglobin) 
was 7.0%. A complete blood count showed neutrophilia (white 
blood cell count: 4,100 × 103/μL, neutrophils 76%), low hemo-
globin values (9.1 g/dL; mean corpuscular volume 92 fL), with 
increased platelet count (428  ×  103/μL). Echocardiography 
revealed LVH, regional contraction abnormalities (mid and api-
cal septum) with moderate EF reduction (~40%). No TdP events 
at ECG monitoring were observed. The patient was treated with 
aspirin, low molecular weight heparin, diuretics, magnesium 
sulfate, potassium chloride, and calcium gluconate, while all 
concomitant QT-prolonging drugs were stopped. In the next 
days, the patient’s clinical condition progressively improved, and 
troponin and electrolyte levels normalized. A parallel shortening 
of the QTc was documented, although it remained significantly 
prolonged (>550  ms). Since inflammatory marker elevation 
persisted, corticosteroids and methotrexate were restarted, and 
at discharge, CRP levels began to reduce (2.39 mg/dL). Notably, 
at this time also QTc was shortened to ~500 ms (Figure S2 in 
Supplementary Material).
Inflammatory Cytokine Measurement
In all patients, a blood sample was obtained within 24  h from 
TdP/marked QTc prolongation occurrence, and levels of IL-6, 
TNFα, and IL-1 were evaluated by multiplex assay for cytokine 
quantification (Bioplex, Bio-Rad, Hercules, CA, USA). In all 
cases, IL-6 was markedly elevated, ~10 to 100 times higher than 
FIGURe 2 | eCG findings in patient 2. (a,B) Atrioventricular dissociation with low-rate PM-induced ventricular beats (45 bpm), alternating with narrow beats from 
a junctional escape revealing QTc prolongation (550 ms). Red vertical lines in lead II show QT interval. (C) Torsades de pointes episode at ECG monitoring.
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including cardiac arrest, is higher than in the general popula-
tion (29). Although specific epidemiological data are, to date, 
completely missing, the above considerations strongly suggest 
that patients with CIA may be at increased risk of TdP. The three 
cases reported here seem to support this view. In particular, it 
should be noted that the two RA subjects belong to a larger cohort 
of 25 consecutive TdP patients prospectively enrolled from 2008 
to 2015 at our institution, independent of ongoing therapies and 
concomitant diseases (2). This corresponds to an 8% incidence 
of RA in our cohort of TdP, a value 8- to 16-times higher when 
compared with the expected incidence of RA in the general popu-
lation, which is ~0.5–1% (30). Consistently, other recent TdP case 
series reported an ~5% RA incidence, however only considered 
as incidental (4, 24, 27). In both our cases, TdP rapidly degener-
ated to cardiac arrest, thus suggesting the possibility that in RA 
patients, this arrhythmia may be frequently undetected due to a 
high propensity of progression to SCD in the short-term.
Increasing evidence indicates that the main pathophysiolog-
ical mechanism underlying CIA-associated QTc prolongation 
reference values, as obtained from an internal reference group of 
healthy controls. Moreover, patient 1 also showed high circulat-
ing levels of TNFα and IL-1 (Table 2).
DIsCUssIoN
The main concept emerging from these cases is that CIA may 
represent a currently overlooked QT-prolonging risk factor, 
potentially contributing in the presence of other “classical” risk 
factors to TdP occurrence. More particularly, our study shows that 
the link found in CIA patients between inflammatory cytokines 
and QTc prolongation is clinically relevant as it is associated with 
an actual risk of developing TdP and SCD.
QTc prolongation is relatively common in CIA patients with 
active disease. In RA subjects, SCD is ~2-times more likely than 
in the general population, with QTc prolongation representing 
an independent predictor for all-cause mortality (4, 5, 7, 20). 
Furthermore, a large population-based study demonstrated 
that in PsA patients, the incidence of ventricular arrhythmias, 
FIGURe 3 | eCG findings on patient 3 on admission. (a,B) T-wave alternans with marked QTc prolongation, ranging from 690 to 870 ms. Red arrows, long and 
short, indicate T-wave changes. Red vertical lines in lead V5 show QT interval, while red asterisks indicate where QTc is calculated (*690 ms; **870 ms).
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is systemic inflammatory activation, acting both indirectly, by 
accelerating the development of structural CVD, and directly, 
by affecting cardiac electrophysiology (4, 10). In particular, 
many basic studies (11–19) demonstrated that inflammatory 
cytokines (IL-6, TNFα, IL-1) induce profound changes in the 
expression and function of potassium and calcium channels 
resulting in a prolonging effect on cardiomyocyte APD, which 
translate to QT interval prolongation on the surface ECG. 
Furthermore, in RA patients, circulating levels of inflammatory 
cytokines correlated with QTc duration, thus indicating that 
also in vivo these mechanisms are of crucial importance (31). 
Accordingly, all our patients had active disease with elevated 
inflammatory markers and cytokine levels. In particular, in 
all cases, circulating IL-6 was markedly increased, suggesting 
a particularly relevant role for this molecule in TdP develop-
ment in these subjects. Experiments in pig ventricular cells 
demonstrated that IL-6 prolongs APD, by enhancing L-type 
calcium current (ICaL) (18) Moreover, in RA anti-cytokine 
therapy with the anti-IL-6-receptor antibody, tocilizumab was 
associated with a rapid (within 3 months) and significant QTc 
shortening, which correlated with the decrease in CRP levels 
(32). Finally, a recent study on a large cohort of women with RA 
demonstrated that inflammation, as assessed by IL-6 circulat-
ing levels, more strongly correlated with fatal than non-fatal 
cardiovascular events (33). Notably, systemic inflammatory 
activation occurring in CIA is in many aspects similar to that 
observed in other chronic inflammatory conditions. Thus, it is 
highly probable that the reported findings have a more general 
significance.
Nevertheless, inflammation alone cannot account for marked 
QTc prolongation observed in our patients. Rather, it probably 
represented a contributing factor synergistically operating with 
the other QT-prolonging factors concomitantly present, prin-
cipally structural heart disease and electrolyte imbalances, and 
also advanced age and endocrine disorders (diabetes mellitus/
metabolic syndrome). In particular, patient 2 was affected with 
complete atrioventricular block, a condition that per se markedly 
increases TdP risk by inducing electrical ventricular remodeling 
7Lazzerini et al. Chronic Arthritis and Torsades de pointes
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(34). Patient 1 presented hypocalcemia, and patient 3 combined 
hypokalemia, hypocalcemia, and hypomagnesemia. Finally, 
patient 3 was also taking several QT-prolonging drugs, while 
patient 1 showed circulating anti-Ro/SSA antibodies. These two 
factors may further reduce the repolarization reserve by inhibit-
ing hERG–potassium channel via pharmacologic or autoimmune 
mechanisms, respectively (1–3).
It is noteworthy that patients 1 and 3 presented with an acute 
coronary syndrome (ACS). Studies demonstrated that in RA 
patients, coronary plaques are more inflamed and susceptible 
to rupture than in non-RA subjects, and the ischemia-driven 
effects on arrhythmogenesis are well recognized. Accordingly, 
when compared to non-RA subjects, RA patients’ ACSs show 
a higher short-term case fatality, and more frequently present 
with SCD (4, 10). Thus, it is plausible that in these two patients, 
systemic inflammation may have simultaneously increased 
myocardial electrical instability both indirectly, by promot-
ing coronary occlusion, and directly by prolonging APD. The 
specific contribution of the direct cytokine-mediated effects 
seems to be relevant. Specifically and despite the recovery from 
myocardial ischemia (and the control of other concomitant 
risk factors), in both patients 1 and 3, TdP and marked QTc 
prolongation persisted until disease activity and systemic 
inflammation were reduced. Recent data from animal models 
strongly support this view, by providing evidence that inflam-
matory activation can markedly enhance the effects of acute 
ischemia in increasing APD duration and ventricular arrhyth-
mia propensity (35, 36).
CoNCLUDING ReMaRKs
In patients with active CIA, the risk of TdP may be higher than 
expected. A relevant role seem to be played by systemic inflam-
matory activation, particularly elevated circulating IL-6 levels, 
via direct electrophysiological effects on the heart. Although large 
prospective studies specifically assessing the actual prevalence of 
TdP events as well as their contribution to the increased SCD risk 
observed in these patients are warranted, this fact should be care-
fully kept in mind, particularly when recognizable risk factors 
are already present and/or the addition of QT-prolonging drugs 
is required.
Intriguingly, such mechanisms may be more generally in effect 
in all the diseases characterized by chronically active systemic 
inflammation, thereby significantly emphasizing the relevance of 
our findings.
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FIGURe s1 | eCG of patient 1 in the long-term follow-up. QTc interval is 
only slightly prolonged (455 ms). Red vertical lines in lead V5 show QT interval.
FIGURe s2 | eCG findings of patient 3 during hospitalization. (a) Day 7: 
QTc 580 ms. (B) Day 13: QTc 500 ms. Red vertical lines in lead V5 show QT 
interval.
ReFeReNCes
1. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et  al. 
Prevention of torsade de pointes in hospital settings: a scientific statement 
from the American Heart Association and the American College of 
Cardiology Foundation. Circulation (2010) 121:1047–60. doi:10.1161/
CIRCULATIONAHA.109.192704 
2. Yue Y, Castrichini M, Srivastava U, Fabris F, Shah K, Li Z, et al. Pathogenesis 
of the novel autoimmune-associated long QT syndrome. Circulation (2015) 
132:230–40. doi:10.1161/CIRCULATIONAHA.115.009800 
3. Lazzerini PE, Yue Y, Srivastava U, Fabris F, Capecchi PL, Bertolozzi I, et al. 
Arrhythmogenicity of anti-Ro/SSA antibodies in patients with torsades de 
pointes. Circ Arrhythm Electrophysiol (2016) 9(4):e003419. doi:10.1161/
CIRCEP.115.003419 
4. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and 
arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J (2016). 
doi:10.1093/eurheartj/ehw208 
5. Chauhan K, Ackerman M, Crowson CS, Matteson EL, Gabriel SE. Population-
based study of QT interval prolongation in patients with rheumatoid arthritis. 
Clin Exp Rheumatol (2015) 33:84–9. 
6. Lazzerini PE, Acampa M, Capecchi PL, Hammoud M, Maffei S, Bisogno S, 
et  al. Association between high sensitivity C-reactive protein, heart 
rate variability and corrected QT interval in patients with chronic 
inflammatory arthritis. Eur J Intern Med (2013) 24:368–74. doi:10.1016/ 
j.ejim.2013.02.009 
7. Panoulas VF, Toms TE, Douglas KM, Sandoo A, Metsios GS, Stavropoulos-
Kalinoglou A, et  al. Prolonged QTc interval predicts all-cause mortality in 
patients with rheumatoid arthritis: an association driven by high inflam-
matory burden. Rheumatology (2014) 53:131–7. doi:10.1093/rheumatology/ 
ket338 
8. Acar G, Yorgun H, Inci MF, Akkoyun M, Bakan B, Nacar AB, et al. Evaluation 
of Tp-e interval and Tp-e/QT ratio in patients with ankylosing spondylitis. 
Mod Rheumatol (2014) 24:327–30. doi:10.3109/14397595.2013.854072 
9. Simsek H, Sahin M, Akyol A, Akdag S, Ozkol HU, Gumrukcuoglu HA, et al. 
Increased risk of atrial and ventricular arrhythmia in long-lasting psoriasis 
patients. ScientificWorldJournal (2013) 2013:901215. doi:10.1155/2013/901215 
10. Lazzerini PE, Capecchi PL, Acampa M, Galeazzi M, Laghi-Pasini F. 
Arrhythmic risk in rheumatoid arthritis: the driving role of systemic 
inflammation. Autoimmun Rev (2014) 13:936–44. doi:10.1016/j.autrev.2014. 
05.007 
8Lazzerini et al. Chronic Arthritis and Torsades de pointes
Frontiers in Cardiovascular Medicine | www.frontiersin.org September 2016 | Volume 3 | Article 31
11. London B, Baker LC, Lee JS, Shusterman V, Choi BR, Kubota T, et  al. 
Calcium-dependent arrhythmias in transgenic mice with heart failure. 
Am J Physiol Heart Circ Physiol (2003) 284:H431–41. doi:10.1152/
ajpheart.00431.2002 
12. Petkova-Kirova PS, Gursoy E, Mehdi H, McTiernan CF, London B, Salama G. 
Electrical remodeling of cardiac myocytes from mice with heart failure due 
to the overexpression of tumor necrosis factor-alpha. Am J Physiol Heart Circ 
Physiol (2006) 290:H2098–107. doi:10.1152/ajpheart.00097.2005 
13. Kawada H, Niwano S, Niwano H, Yumoto Y, Wakisaka Y, Yuge M, et al. Tumor 
necrosis factor-alpha downregulates the voltage gated outward K+ current in 
cultured neonatal rat cardiomyocytes: a possible cause of electrical remodeling 
in diseased hearts. Circ J (2006) 70:605–9. doi:10.1253/circj.70.605 
14. Panama BK, Latour-Villamil D, Farman GP, Zhao D, Bolz SS, Kirshenbaum LA, 
et al. Nuclear factor kappaB downregulates the transient outward potassium 
current I(to,f) through control of KChIP2 expression. Circ Res (2011) 
108:537–43. doi:10.1161/CIRCRESAHA.110.229112 
15. Fernández-Velasco M, Ruiz-Hurtado G, Hurtado O, Moro MA, Delgado C. 
TNF-alpha downregulates transient outward potassium current in rat 
ventricular myocytes through iNOS overexpression and oxidant species 
generation. Am J Physiol Heart Circ Physiol (2007) 293:H238–45. doi:10.1152/
ajpheart.01122.2006 
16. Wang J, Wang H, Zhang Y, Gao H, Nattel S, Wang Z. Impairment of HERG 
K(+) channel function by tumor necrosis factor-alpha: role of reactive oxygen 
species as a mediator. J Biol Chem (2004) 279:13289–92. doi:10.1074/jbc.
C400025200 
17. Li YH, Rozanski GJ. Effects of human recombinant interleukin-1 on electrical 
properties of guinea pig ventricular cells. Cardiovasc Res (1993) 27:525–30. 
doi:10.1093/cvr/27.3.525 
18. Hagiwara Y, Miyoshi S, Fukuda K, Nishiyama N, Ikegami Y, Tanimoto K, 
et  al. SHP2-mediated signaling cascade through gp130 is essential for LIF-
dependent I CaL, [Ca2+]i transient, and APD increase in cardiomyocytes. 
J Mol Cell Cardiol (2007) 43:710–6. doi:10.1016/j.yjmcc.2007.09.004 
19. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Long QT syndrome:an emerging 
role for inflammation and immunity. Front Cardiovasc Med (2015) 2:26. 
doi:10.3389/fcvm.2015.00026 
20. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Ballman KV, 
Roger VL, et al. Increased unrecognized coronary heart disease and sudden 
death in rheumatoid arthritis. A population-based cohort study. Arthritis 
Rheum (2005) 52:402–11. doi:10.1002/art.20853 
21. Di Lorenzo M, Schiavo B. Rheumatoid heart: report of a case with endomyo-
cardial injury and severe arrhythmias. G Ital Cardiol (1978) 8:886–91. 
22. Tsuji M, Dowaki M, Yamada A, Nakura Y, Takahashi S, Hatano M, et  al. 
A case of anti-RNP antibody positive malignant rheumatoid arthritis with 
pulmonary hypertension. Nihon Naika Gakkai Zasshi (1991) 80:1673–5. 
doi:10.2169/naika.80.1673 
23. Lai D, Brown G, MacDonald I. Clarithromycin-induced prolonged QT 
syndrome. Can J Hosp Pharm (1996) 49:33–5. 
24. Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB. Gatifloxacin-associated 
corrected QT interval prolongation, torsades de pointes, and ventricular 
fibrillation in patients with known risk factors. Clin Infect Dis (2002) 34:861–3. 
doi:10.1086/339075 
25. Bruggisser M, Ratz Bravo A, Brodmer M. Medication associated long QT 
syndrome. Praxis (2009) 98:1409–15. doi:10.1024/1661-8157.98.24.1409 
26. Vilaseca-Corbera M, Vázquez-Oliva G, Campoamor-Cela C, Zamora-
Cervantes A, Bassanyanes-Vilarrasa J, Massa-Puig R. Extreme QT interval 
prolongation and helicoid ventricular tachycardia (torsade de pointes) in 
non-ST-elevation acute coronary syndrome. Rev Esp Cardiol (2012) 65:294–6. 
doi:10.1016/j.recesp.2011.05.015 
27. Vieweg WV, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk  A. 
Clarithromycin, QTc interval prolongation and torsades de pointes: 
the need to study case reports. Ther Adv Infect Dis (2013) 1:121–38. 
doi:10.1177/2049936113497203 
28. Tampi RR, Balderas M, Carter KV, Tampi DJ, Moca M, Knudsen A, et  al. 
Citalopram, QTc prolongation, and torsades de pointes. Psychosomatics (2015) 
56:36–43. doi:10.1016/j.psym.2014.09.002 
29. Chiu HY, Chang WL, Huang WF, Wen YW, Tsai YW, Tsai TF. Increased risk of 
arrhythmia in patients with psoriatic disease: a nationwide population-based 
matched cohort study. J Am Acad Dermatol (2015) 73:429–38. doi:10.1016/ 
j.jaad.2015.06.023 
30. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet (2010) 
376:1094–108. doi:10.1016/S0140-6736(10)60826-4 
31. Adlan AM, Panoulas VF, Smith JP, Fisher JP, Kitas GD. Association between 
corrected QT interval and inflammatory cytokines in rheumatoid arthritis. 
J Rheumatol (2015) 42:421–8. doi:10.3899/jrheum.140861 
32. Lazzerini PE, Acampa M, Capecchi PL, Fineschi I, Selvi E, Moscadelli V, et al. 
Antiarrhythmic potential of anti-cytokine therapy in rheumatoid arthritis:To-
cilizumab reduces QTc interval by controlling systemic inflammation. Arthritis 
Care Res (Hoboken) (2015) 67:332–9. doi:10.1002/acr.22455 
33. Mackey RH, Kuller LH, Deane KD, Walitt BT, Chang YF, Holers VM, et al. 
Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardio-
vascular disease risk in the women’s health initiative. Arthritis Rheumatol 
(2015) 67:2311–22. doi:10.1002/art.39198 
34. Oros A, Beekman JD, Vos MA. The canine model with chronic, complete 
atrio-ventricular block. Pharmacol Ther (2008) 119:168–78. doi:10.1016/ 
j.pharmthera.2008.03.006 
35. De Jesus NM, Wang L, Herren AW, Wang J, Shenasa F, Bers DM, et  al. 
Atherosclerosis exacerbates arrhythmia after myocardial infarction: role of 
myocardial inflammation. Heart Rhythm (2015) 12:169–78. doi:10.1016/ 
j.hrthm.2014.10.007 
36. Yu X, Patterson E, Huang S, Garrett MW, Kem DC. Tumor necrosis factor 
alpha, rapid ventricular tachyarrhythmias, and infarct size in canine models 
of myocardial infarction. J Cardiovasc Pharmacol (2005) 2005(45):153–9. 
doi:10.1097/01.fjc.0000151930.12026.b7 
Conflict of Interest Statement: We do not have any financial support or other 
benefits from commercial sources for the work reported on in the manuscript, or 
any other financial interests, which could create a potential conflict of interest or 
the appearance of a conflict of interest with regard to the work.
Copyright © 2016 Lazzerini, Capecchi, Bertolozzi, Morozzi, Lorenzini, Simpatico, 
Selvi, Bacarelli, Acampa, Lazaro, El-Sherif, Boutjdir and Laghi-Pasini. This is an 
open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these terms.
